

Product datasheet for RC226906L3V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

CD164 (NM_001142403) Human Tagged ORF Clone Lentiviral Particle

Product data:

Product Type: Lentiviral Particles

Product Name: CD164 (NM_001142403) Human Tagged ORF Clone Lentiviral Particle

Symbol: CD164

Synonyms: DFNA66; endolyn; MGC-24; MGC-24v; MUC-24

Mammalian Cell

Selection:

Puromycin

Vector: pLenti-C-Myc-DDK-P2A-Puro (PS100092)

Tag: Myc-DDK

ACCN: NM_001142403

ORF Size: 567 bp

ORF Nucleotide

The ORF insert of this clone is exactly the same as(RC226906).

Sequence:

OTI Disclaimer:

The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing

variants is recommended prior to use. More info

OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression

varies depending on the nature of the gene.

RefSeg: NM 001142403.1

 RefSeq ORF:
 570 bp

 Locus ID:
 8763

 UniProt ID:
 Q04900

Cytogenetics: 6q21

Protein Families: Secreted Protein, Transmembrane

Protein Pathways: Lysosome MW: 19.8 kDa







Gene Summary:

This gene encodes a transmembrane sialomucin and cell adhesion molecule that regulates the proliferation, adhesion and migration of hematopoietic progenitor cells. The encoded protein also interacts with the C-X-C chemokine receptor type 4 and may regulate muscle development. Elevated expression of this gene has been observed in human patients with Sezary syndrome, a type of blood cancer, and a mutation in this gene may be associated with impaired hearing. [provided by RefSeq, Oct 2016]